Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2009

View Archived Issues

Novel tools for post-transplant tacrolimus dose optimization reported

Banyu describes 4-sulfonylpiperidine derivatives for the treatment of diabetes

Kitasato Institute and Kyowa Hakko Kirin claim novel KB-3346-5 substances as antiinfective agents

Improved early virologic response rates seen with GI-5005 in phase II HCV study

Preclinical data on phase I antiangiogenic mAb, PF-03446962, presented

AEZS-126, a new orally bioavailable PI3K inhibitor shows preclinical antitumor activity

Intravitreal viral delivery of VEGF antagonist developed as therapy for ocular neovascularization

Intarcia completes enrollment in phase Ib clinical study of ITCA-650 in type 2 diabetes

Novel multitargeted kinase inhibitor displays potent antitumor activity in preclinical cancer models

Choongwae patents GSK-3beta inhibitors for the treatment of Alzheimer's disease

Novel PI3K inhibitors for cancer treatment jointly patented by Genentech and Roche

Antisense begins pivotal phase III trabedersen trial in aggressive brain tumors

Avila Therapeutics' novel agent AVL-181 silences HCV protease activity

Peregrine presents preliminary phase II bavituximab data in breast cancer

Pharmasset and Roche dose first patient in phase IIb clinical trial of HCV drug R-7128

CHMP recommends approval of pediatric formulation of Tracleer in PAH

Clinical study shows anti-HCV efficacy of NIM-811 with peginterferon

Janssen receives Japanese approval to market Risperdal Consta for schizophrenia

European Commission grants Wyeth marketing authorization for Conbriza

Novel Aurora kinase inhibitors claimed by Bayer for cancer treatment

FDA accepts for review Theravance's complete response for telavancin in cSSSI

FDA grants orphan drug designation to Pharming's Prodarsan for Cockayne syndrome

Phase III Nexavar trial in advanced melanoma does not meet primary endpoint

Phase II GSK-1838262 results reported for pain in diabetic peripheral neuropathy

Sepracor reports preliminary phase III Omnaris results in allergic rhinitis

Once-daily antiepileptic Zebinix approved in the European Union

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...